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Breast cancer is globally the most common malignancy in women. Her2-targeted monoclonal antibodies are established treatment
modalities, and vaccines are in late-stage clinical testing in patients with breast cancer and known to promote tumour-killing through
mechanisms like antibody-dependent cellular cytotoxicity. It is therefore increasingly important to study immunological consequences
of conventional treatment strategies. In this study, functional tests and four-colour flow cytometry were used to detect natural killer
(NK)-cell functions and receptors as well as T-cell signal transduction molecules and intracellular cytokines in preoperative breast
cancer patients, and patients who had received adjuvant radiotherapy or adjuvant combined chemo-radiotherapy as well as in age-
matched healthy controls. The absolute number of NK cells, the density of NK receptors as well as in vitro quantitation of functional
NK cytotoxicity were significantly higher in preoperative patients than the post-treatments group and controls. A similar pattern was
seen with regard to T-cell signalling molecules, and preoperative patients produced significantly higher amounts of cytokines in NK
and T cells compared to other groups. The results indicate that functions of NK and T cells are well preserved before surgery but
decrease following adjuvant therapy, which may speak in favour of early rather than late use of immunotherapeutic agents such as
trastuzumab that may depend on intact immune effector functions.
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Breast cancer (BC) is the most common malignancy in women and
the principal cause of death from cancer among women globally
(Bray et al, 2004). Despite impressive progress in diagnosis and
treatment (Hudis, 2003), a substantial fraction of women fail
conventional treatments (i.e. surgery, radiation treatment and/or
chemotherapy) and ultimately relapse and die (Cheng et al, 2004).
Her-2 targeting monoclonal antibodies such as trastuzumab, given
as adjuvant therapy, have significantly improved the relapse-free
survival of breast cancer patients (Chan et al, 2006). However, it is
not yet clear whether adjuvant trastuzumab treatment ought to be
incorporated early, that is together with chemotherapy, or late,
that is after end of adjuvant chemo-radiotherapy (Gennari et al,
2004). In addition to their direct apoptosis-inducing effect on
tumour cells via the antagonistic effect on critical tumour cell
receptors, trastuzumab is known to promote immune-mediated
destruction of tumour cells by mechanisms such as antibody-
dependent cellular cytotoxicity (ADCC) (Arnould et al, 2006), the
mechanisms of which may be critically dependent on a functioning
immune system. Additional immune function-dependent modal-
ities for treatment of breast cancer that are currently in
development include vaccines that induce active immunity against
the cancer in patients (Yi et al, 2006). Thus, the above approaches
to adjuvant therapy of breast cancer are impingent on the
preservation of immune function in the patient during and
following tumour debulking procedures.
Previous studies have reported that functional activity of natural
killer (NK) cells is decreased and these cells undergo spontaneous
apoptosis in patients with cancer (Konjevic and Spuzic, 1992;
Bauernhofer et al, 2003). In contrast, increased NK-cell numbers
and NK activity have also been reported in breast cancer and colon
cancer before neo-adjuvant immunotherapy and correlated to time
to treatment failure (Nicolini et al, 1996; Murta et al, 2000; Liljefors
et al, 2003). Abnormalities in expression of activation molecules
such as TCR , ZAP70 and p56 lck protein expression using western
blot in BC (Kurt et al, 1998) as well as impaired expression of
interferon-g (IFN-g) in BC and lung cancer using enzyme-linked
immunosorbent assay (Caras et al, 2004) have been described.
Received 10 January 2007; revised 15 May 2007; accepted 15 May 2007;
published online 5 June 2007
*Correspondence: Professor H Mellstedt, Department of Oncology
(Radiumhemmet), Karolinska University Hospital, Stockholm SE-17176,
Sweden; E-mail: hakan.mellstedt@karolinska.se
British Journal of Cancer (2007) 97, 105–111
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sHowever, to our knowledge no studies have examined the effects of
conventional adjuvant breast cancer therapy on the immune
function in these patients. Given the emerging adjuvant use of
trastuzumab (as well as future vaccines), the present study was
conducted to investigate the NK- and T-cell function in breast cancer
patients before and after primary treatment with surgery and
adjuvant chemo-radiotherapy with the intention of delineating any
potential immune aberrations that may result from therapy. The
results would be beneficial in providing a scientific basis to integrate
adjuvant immunotherapy in an optimal way in such patients.
MATERIALS AND METHODS
Patients and treatments
Fifty women with BC and 11 healthy age-matched controls were
included. The patients were all treated in the same surgery and
oncology unit, according to the National Treatment Guidelines.
Patients were treated according to the Helsinki declaration on the
participation of human subjects in medical research and all blood
samples were collected between 0800 and 0900 hours (to minimise
diurnal influence) after obtaining informed consent as per
protocols approved by the local ethical committee. Patient
characteristics are shown in Table 1.
Blood samples from pretreatment (n¼9) (PT group) was drawn
1–3 days before surgery and from post-treatment patients (n¼41)
(RT, RTþCT groups). Median time was 45 (5–100) and 120 (54–
164) days after finishing adjuvant therapy.
About 50Gy total radiation, fractioned in 2Gy doses was
delivered to the breast. Patients with lymph node involvement
(n¼18) had additional radiation delivered to the adjacent lymph
nodes. Twenty patients received radiotherapy alone (RT group)
and 21 received a combination of radiation and chemotherapy
(RTþCT group) with 5-fluorouracil, epirubicin and cyclophos-
phamide (FEC). Comparable number of patients in both arms
received adjuvant tamoxifen therapy at the time of testing.
Monoclonal antibodies and other reagents
Antibodies conjugated with FITC, PE, PerCP or APC against the
surface molecules CD3, CD4, CD8, CD19, CD25, CD28, CD56,
CD94, CD161 and NKB1 and the cytokines IFN-g, IL-2 and IL-4, as
well as isotype-matched negative controls were commercially
purchased from Becton-Dickinson (BD) (Mountain view, CA,
USA). Mabs against the signal transduction molecules P56
lck,
p59
fyn, Zap70 and PI3k were purchased from Transduction
Laboratories (Lexington, KY, USA) and antibody against CD3z
from Bio Site (Stockholm, Sweden). Saponin, PMA and ionomycin
were purchased from Sigma (St Louis, MO, USA) and Brefeldin A
and goat antimouse Mab were obtained from BD.
Isolation of peripheral blood mononuclear cells and cell
culture conditions
Peripheral blood mononuclear cells (PBMNC) were isolated from
heparinised blood by separation on a Ficoll–Isopaque gradient
(Amersham Pharmacia Biotech AB, Uppsala, Sweden). To assess
the ability of T and NK cells to produce cytokines in response to
stimuli, 1–2 10
6cellsml
 1 were stimulated with 25ngml
 1 PMA
and 1mgml
 1 ionomycin in RPMI-1640 medium containing 10%
heat-inactivated fetal calf serum (FCS), 2mMl
 1 glutamine,
100Uml
 1 penicillin, 100mgml
 1 streptomycin (Gibco BRL,
Paisley, UK) and 10mgml
 1 Brefeldin A in Falcon tubes.
Unstimulated samples were set up in parallel, but without PMA
and ionomycin. The Falcon tubes were incubated at 371Ci na5 %
CO2 for 4h.
Cellular staining and flow cytometry
Flow-cytometric analyses were carried out using a FACSCalibur
(BD) as described in a previous study (Mozaffari et al, 2004). Fresh
cells were used whenever possible, failing which cryopreserved
cells, ficolled to remove dead cells and debris, were used. Briefly,
5 10
5 cells per tube were incubated with the appropriate
concentration of antibodies or isotype controls (2–10ml) for
30min on ice. For indirect staining of intracellular cytokines and
signalling molecules, the cells were permeabilised with 0.1%
saponin and incubated with the primary antibodies or isotype
controls for 30min at room temperature in the dark. Goat anti-
mouse FITC-conjugated secondary antibody was then added to the
washed cells and incubated for 10min. Flow-cytometry gating was
used to detect and separate lymphocytes and to analyse the T and
NK cells. Criteria for positive staining were set at fluorescent
intensities displayed by o1% of the cells stained with the isotype
controls. Threshold frequencies of cytokine production by
unstimulated control cells were subtracted from the percentage
of cytokine producing cells quantified after stimulation.
Calculation of absolute cell numbers
Lymphocytes expressing NK receptors and T-cell subset markers
as determined by flow cytometry were expressed as a percentage of
the total population. To determine the number of the populations
per millilitre of blood, the percentage fraction of lymphocytes was
multiplied by the number of lymphocytes per litre as determined
by an automated differential blood count on the same sample.
NK- cell-mediated cytotoxicity
Natural killer cell function was measured in vitro using a
chromium release assay. Briefly, NK-sensitive K562 cells were
Table 1 Patient characteristics
Post treatment
b
(n¼41)
Group
Pretreatment
a
(n¼9)
RT
(n¼20)
RT+CT
(n¼21)
Age (range) (43–75) (52–80) (38–69)
Type of surgery
Mastectomy — 3 2
Breast conservation — 17 19
Lymph nodes
Axillary clearance 0 5 14
Sentinel node 8 11 7
No axillary dissection 1 4 0
Cancer in situ 12 0
No. of involved nodes
p30 0 1 1
4–8 1 1 4
X90 0 1
negative 8 15 5
ER+ 8 17 14
PR+ 8 10 9
HER2+ 1 4
HER2  16
Tumour size mm, median
(range)
14 (5–50) 17 (7–30)
o2cm 7 13 16
X2cm 2 7 5
Adjuvant tamoxifen 5 11 15
ER+¼estrogen receptor positive; HER2+¼human epidermal growth factor
receptor 2; PR+¼progestron receptor positive.
aBlood samples were collected
1–3 days before primary surgery.
bBlood samples collected after a median time 40
days.
NK-cell and T-cell functions in breast cancer
F Mozaffari et al
106
British Journal of Cancer (2007) 97(1), 105–111 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
slabelled with 100mCi Na2
51CrO4 (37MBq, 1mCi, Amersham, UK)
for 1h and cocultured with effector cells for 4h at various effector:
target cell ratios in triplicates in 96-well plates (50:1, 25:1, 12.5:1,
6.25:1). Spontaneous
51Cr release was determined by incubating
target cells alone, and total release by lysing labelled cells with 5%
Triton X-100. After incubation the supernatant was counted in a
gamma counter. NK cytotoxic activity was calculated as number of
lytic units (LU) per 10
6 effector cells. One lytic unit is the number
of effector cells capable of lysing 30% of the target cells and the
calculations were performed using computer software kindly
provided by Dr T Whiteside (University of Pittsburgh, Pittsburgh,
PA, USA).
Proliferation assay
Mononuclear cells from patients or healthy volunteers
(1 10
5cellswell
 1) were incubated in medium alone, medium
containing 10mgml
 1 phytohaemagglutinin (PHA) (Gibco BRL) or
2.5mgml
 1 of mycobacterial purified protein derivative (PPD)
(National Serum Institute, Copenhagen, Denmark) in a 96-well
culture plate. Cultures were incubated for 3 days and 1mCiwell
 1
3H-thymidine (Amersham Pharmacia Biotech, Uppsala, Sweden) was
added to each well for the final 16–18h. Cells were harvested and the
incorporated radioactivity was measured in a b-counter (Micro b
1450, Wallace, Turku, Finland). Results were reported as stimulation
index, calculated as the ratio of radioactivity of cells incubated with
PHA or PPD and the radioactivity of control cultures.
Statistical methods
The Kruskal–Wallis or Mann–Whitney U-test was used to
calculate statistical significance in expression of cell surface
molecules among the four groups of patients. Simple linear
regression analysis was used to explore the possible correlation
between immunological parameters, for example LU and NK
receptors. Results were considered to be statistically significant for
Po0.05. Data from the phenotypic analyses as well as functional
assays from healthy donors and patients had a normal distribution
pattern.
RESULTS
NK cells
Four-colour flow cytometry demonstrated significantly higher
absolute numbers of NK cells (CD3
 CD56
þ) in the PT group
compared to RT and RTþCT groups as well as to healthy controls.
In particular, the RTþCT group had significantly lower number
of NK cells than all other groups (Table 2). The frequency of
cells expressing the NK-cell receptors CD161 (Figure 1), NKB1
(Figure 2) and CD94 (not shown) demonstrated the same pattern.
There was also a significantly higher NK cytotoxicity in the PT
group in comparison to post-treatment group and healthy
volunteers, with the lowest cytotoxicity observed in the RTþCT
group and in healthy volunteers (Table 2).
Intracellular staining for IFN-g in NK cells revealed comparable
patterns to the LU and overall NK frequency. Significantly higher
frequency of IFNg-producing NK cells was found in patients before
treatment compared to all other groups (Table 2).
Analysis of regulatory T cells and T-cell surface markers
Both RT and RTþCT had a profound effect in decreasing the
numbers of circulating T cells with CD4
þ cells being affected to a
greater extent than CD8
þ cells (Table 2). We subsequently
analysed the Treg subsets in the patients before and after therapy
in comparison to normal donors and also examined the activation
markers on T cells. Tregs were measured as frequency
of CD3þCD4þCD25
hi cells (Figure 3). The frequency of
Table 2 Lymphocyte subsets in patients and healthy donors
C PT RT RT+CT
WBC
a 6.9 10
370.4 (5.6–10 10
3)7  10
370.5 (4.5–9.2 10
3) 5.7 10
370.3 (4.1–8.5 10
3) 4.3 10
370.2 (3.2–5.3 10
3)
Lymphocyte
b 2 10
370.2 (1.1–3 10
3) 1.9 10
370.1 (1.3–2.2 10
3) 1.7 10
370.1 (0.8–3 10
3) 1.1 10
370.1 (0.6–1.7 10
3)
CD3
+CD4
+c 8587107 (385–1512) 782777 (435–1045) 625779 (230–1572) 336724 (198–606)
CD3
+CD8
+d 371776 (133–885) 260738 (102–399) 244732 (95–447) 311739 (87–476)
CD3
 CD56
+e 160732 (49–410) 293747 (74–462) 144723 (10–428) 84712 (7.7–150)
IFN-g+NK cell frequency
f 2.170.6 (0.0–6.5) 6.270.8 (2–9.8) 3.570.6 (0.1–10) 4.470.6 (1–11)
LU
g 2.670.4 (1–6.6) 1372.9 (1.9–32.5) 6.671.2 (1.3–19.5) 4.470.6 (0.3–10.4)
Absolute number (mean7s.e.m.) of WBC, lymphocytes, CD4/CD8T cells, NK cells per microlitre. Frequency of NK cells expressing IFN-g and NK lytic unit in healthy donors (C)
and patient groups before treatment (PT) after radiation therapy (RT) and after radiation+chemotherapy (RT+CT).
aThe difference between the healthy donors and post-
treatment group RT+CT were significant at Pp 0.001. The difference between pretreatment and post-RT was significant at Pp0.05. The difference between PT and RT+CT as
well as between RT and RT+CT was significant at Pp0.001.
bThe difference between the healthy donors and post-treatment group RT+CT were significant at Pp0.01. The
difference between PT and RT+CT as well as between RT and RT+CT was significant at Pp0.01.
cHealthy donors, PT and RT groups did not differ significantly. All of these
groups had significant difference compared to RT+CT (Pp0.01–0.001).
dNo significant differences between the patient groups or normal donors.
eElevation in NK cells in PT
patients compared to healthy volunteers was significant at Pp0.05. RT+CT patients had significant decrease compared to healthy donors (Pp0.05) as well as PT patients
(Pp0.001).
fNormal donors had decreased numbers of IFN-g-positive cells compared to PT (Pp0.01) as well as RT+CT groups (Pp0.05). Decrease in RT group compared to
PT was also significant (Pp0.05).
gNormal donors had decreased number of lytic units compared to PT and RT groups (Pp0.01–0.001). Number of lytic units in PT group was
elevated compared to RT (Pp0.05) as well as RT+CT groups (Pp0.01).
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Figure 1 Absolute number of CD161
þNK cells in normal control
donors (C) (n¼11), pretreatment (PT) (n¼9), post-treatment radiation
(RT) (n¼20) and post-treatment radiation/chemotherapy (RTþCT)
(n¼21) treated breast cancer patients. The box represents the 25th to
75th percentiles. The line in the middle of the box represents the median.
The top whisker is drawn from the value associated with the 75th to the
90th percentile, the bottom one associated with the 25th to the 10th
percentile. The outliers show the highest and lowest 10% of observed
values. *Po 0.05, **Po 0.01 and ***Po 0.001.
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hi as well as CD8þCD25
hi T cells was significantly
reduced in pretreatment patients (Po0.05). There was however a
significant increase in CD8þCD25
hi in patients after adjuvant
therapy compared to pretreatment (Figure 4). The fraction of
CD28
þ T cells did not differ between patients before treatment
and healthy volunteers. However, patients who had received
therapy as in particular the RTþCT group had a significantly
reduced number of CD4þCD28þ T cells (Figure 5).
Intracellular T-cell signalling molecules
Patients tested before surgery had similar number of T cells
expressing various signalling molecules as the control donors,
whereas post-treatment patients, particularly in the RTþCT
group, had a significantly reduced number of CD4
þ cells
expressing Zap70, CD3z, P56
lck, p59
fyn and PI3k. There were
no significant differences in CD8
þ T cells expressing signalling
molecules between the groups (data not shown). An example
(ZAP70) of the staining pattern of intracellular T-cell signalling
molecules in CD4T cells is shown in Figure 6. In addition
to frequency of cells, the intensity of expression of the intracellular
molecules was also examined using the MFI (mean fluorescence
intensity) criterion. In this analysis, these were only marginal
differences between the patients groups and controls as
exemplified in Figure 7A (CD8þCD3zþ cells) and B
(CD8þZAP70þ cells).
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Figure 2 Absolute number of NKB1
þNK cells in normal control donors
(C) (n¼11), pretreatment (PT) (n¼9), post-treatment radiation (RT)
(n¼20) and post-treatment radiation/chemotherapy (RTþCT) (n¼21)
treated breast cancer patients. For symbols see Figure 1.
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Figure 3 Flow cytometric analysis of CD4
þCD25
high and CD4
þCD25
þ T cells in healthy donors and breast cancer patients. A minimum of 20000
events in the lymphocyte gate was calculated during acquisition and the analyses was performed on all events calculated. Numbers in the plot indicate the
percentage of cells within the respective rectangle.
−10
0
10
20
30
40
50
60
C
D
8
+
C
D
2
5
+
 
c
e
l
l
s
 

l
−
1
C PT RT RT+CT
**
**
*
*
Figure 4 Absolute number of CD25
high expressing CD8 T cells in
normal control donors (C) (n¼11), pretreatment (PT) (n¼9), post-
treatment radiation (RT) (n¼20) and post-treatment radiation/chemo-
therapy (RTþCT)( n¼21) treated breast cancer patients. For symbols
see Figure 1.
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Frequency of IFN-g, IL-4 and IL-2 producing CD4 and CD8T cells
was analysed by intracellular staining and flow cytometry
following activation of the T cells with PMA/ionomycin. As shown
in Figure 8A (CD4) and B (CD8), there was no major difference
in IFN-g-producing T cells in patients compared to healthy
volunteers, even though patients in RT group demonstrated some
reduction in the frequency of IFN-g-producing T cells. The
frequency of IL-4-producing CD4 cells was significantly higher in
patients before treatment compared to healthy volunteers (Po
0.001) and patients who received RT (Po0.05) (Figure 9A). There
was no significant differences in IL-4-producing CD8T cells
between the groups (data not shown). The pattern of IL-2
production was similar to that of IL-4 and a significantly higher
level of IL-2-producing CD4T cells were detected in patients before
therapy compared to all other groups (Po0.01 to o0.05). There
were no significant differences between the groups regarding CD8T
cell healthy volunteers (Po0.01) (Figure 9B). Similar results were
observed in CD8T cells producing IL-2 (data not shown).
PPD and PHA T-cell response
There was no difference in response to PPD between healthy
volunteers and patients before therapy; however, PPD response
was significantly lower in the RT group, when compared to
patients before treatment (Po0.05). Although an increased level of
PHA-induced proliferation response was seen between pretreat-
ment patients and healthy volunteers, the observed difference was
not statistically significant (data not shown).
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Figure 5 Absolute number of CD28 expressing CD4 T cells in normal
control donors (C) (n¼11), pretreatment (PT) (n¼9), post-treatment
radiation (RT) (n¼20) and post-treatment radiation/chemotherapy
(RTþCT) (n¼21) treated breast cancer patients. For symbols see
Figure 1.
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normal control donors (C) (n¼11), pretreatment (PT) (n¼9), post-
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therapy (RTþCT)( n¼21) treated breast cancer patients. For symbols
see Figure 1.
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Figure 8 Percentage of IFN-g-producing T cells in normal control
donors (C) (n¼11), Pretreatment (PT) (n¼9), post-treatment radiation
(RT) (n¼20) and post-treatment radiation/chemotherapy (RTþCT)
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symbols see Figure 1.
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There is a great need to develop approaches for primary therapy
of solid tumours that preserve immune function since ADCC-
promoting therapeutic antibodies, such as trastuzumab and
anticancer vaccination, are being increasingly developed as
adjuvant treatment modalities (Arnould et al, 2006). With this
objective in mind, this study aimed to examine the various aspects
of NK- and T-cell functions in pretreatment and post-adjuvant
treatment of breast cancer patients.
Untreated breast cancer patients demonstrated increased levels
of NK cells in comparison to healthy subjects, but the levels were
markedly reduced following therapy in both RT and RTþCT
patients. The upregulation was manifested as increased frequency
of CD3
 CD56
þ cells and increased lytic activity against K562
targets. Additionally the NK markers CD162, NKB1, CD94 and the
number of IFN-g-producing NK cells were increased in pretreat-
ment patients which decreased post-therapy. Since lymphocyte
counts in pretreatment patients and healthy volunteers were not
significantly different, it appears that both the numbers and
functional activity of NK cells were increased in patients before
treatment. The augmented NK-cell cytotoxicity may be a result of
activation of the innate immune system by the malignant process
and/or is a result of defective regulation of NK cells in the patients.
NK cells are the principal mediators of ADCC (Henney et al, 1981;
Rosenberg et al, 1987). Recent work has provided further rationale
for maintaining NK function in patients, especially those eligible
for monoclonal antibody-based therapeutic regimens. ADCC has
been demonstrated to be an important mechanism for the in vivo
effects of antibodies like trastuzumab and rituximab (Clynes et al,
2000). Although NK cells are important effectors of ADCC,
their ability to function in ADCC may be reduced with advanced
malignancy (Kono et al, 2002) as well as following radio-
chemotherapy (present study), possibly owing to defective
expression of NK cell-triggering receptors (Costello et al, 2002).
Our data and these previously published studies suggest the use of
early, rather than late, adjuvant therapy treatment protocols for
patients with breast cancer.
As expected, patients had a significant decrease in circulating T
cells after therapy, with helper T cells being affected to a greater
extent than cytotoxic T cells. However, the low numbers of
circulating CD4
þCD25
high as well as CD8
þCD25
high in patients
before treatment was a surprising finding and in contrast to earlier
reports (Liyanage et al, 2002), showing an increased proportion of
CD4
þ/CD25
þ cells in breast and pancreatic cancer patients. Some
of the contributing factors leading to the discrepant results may be
diverse patient characteristics as well as the fact that we calculated
the results as absolute number of the cells rather than percentage
frequency. The increased production of IL-2 following in vitro
stimulation of cells from patients before treatment may also be
due to the low absolute numbers of CD4
þCD25
þ T cells and,
consequently, lesser inhibitory activity. The absolute numbers of
CD4
þCD25
þ T cells as well as CD4
þCD25
high did not change
significantly following treatment but a significant increase in the
number of CD8
þCD25
þ T cells as well as CD8
þCD25
high was
observed compared to patients before therapy. It is interesting to
notice that RT has an effect on increasing the absolute number of
CD4
þCD25
high and specifically on CD8
þCD25
high. CD8
þCD25
high
cells are also known to serve as regulatory T cells quite like
their CD4
þCD25
þ counterparts (Bisikirska et al, 2005; Maggi
et al, 2005).
An interesting observation was that RTþCT treatment had
better preservation of IFN-g secretion by CD4
þ and CD8
þ cells as
well as better preservation of IL-2 secretion by CD4
þ cells
compared to RT arm. While the exact mechanism is not known,
studies in animal models have shown that a single administration
of cyclophosphamide biases the immune system in favour of a Th1
response and facilitates the secretion of cytokines such as IL-2 and
IFN-g (Matar et al, 2002). The striking similarity of our results
demonstrating that RTþCT patients had higher levels of IL-2 and
IFN-g-secreting T cells leads us to speculate that the cyclopho-
sphamide included in the FEC regimen may be responsible for this
effect.
The ability of T cells to transduce signals to the nucleus
following engagement of the TCR is a key component in the
initiation of an immune response. The intracellular downstream
signalling molecules, CD3z, Zap70, P56
lck, p59
fyn and PI3k,
were significantly reduced in the patients following treatment
and the reduction was more pronounced in radiation/chemother-
apy patients. There was no significant difference in frequencies
of signalling molecules in patients before therapy, compared
to healthy volunteers. However, the intensity of CD3z expression
in CD8T cells measured as MFI was significantly downregulated.
Zap70 showed a significant upregulation in T cells in patients
before treatment, compared to healthy volunteer, which further
contributed to the defective T-cell function in breast cancer
patients. Our result support and extend the previous findings
of Kurt et al (1998), who demonstrated decreased P56
lck, CD3z
and Zap70 protein expression in 4 of 14 breast cancer
patients. However, in contrast to our study, 10 of 14 patients
were in stage IV disease and had been previously treated
with chemotherapy or hormonal therapy. Moreover, the signa-
lling molecules were examined in our study using flow
cytometry, a technique known to be more sensitive and
quantitative compared to western blotting used in the report of
Kurt et al (1998). Our data also indicate that T-cell function
was negatively affected by treatment, especially in the RTþCT
group. It has been previously shown that cytotoxic T-cell
number correlate with clinical prognosis in breast cancer patients
(Blake-Mortimer et al, 2004) and that localised radiation can
cause transiently a systemic effect on T-cell function (Berger et al,
1990). Treatment strategies dependent on the integrity of T-cell
function, such as vaccination approaches (Morse, 2000), could
potentially be more efficacious if initiated before radio-chemo-
therapy, or following recovery of T-cell function after cessation of
therapy.
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on optimal use of monoclonal antibodies and on generation of
T-cell-mediated immunity by vaccination strategies. Thus, the
negative effects of radiation and/or chemotherapy on NK- and
T-cell activity in breast cancer are worth considering when new
antibody and vaccine trials are designed in patients with breast
cancer.
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